Literature DB >> 15262239

Positron emission tomography in clinical neurology.

Karl Herholz1, W-D Heiss.   

Abstract

Positron emission tomography (PET) imaging in clinical neurology serves several purposes: differential diagnosis, especially in the early stage of neurologic disorders, description of pathophysiologic changes that are responsible for manifestation and course of a disease, and evaluation and follow-up of treatment effects. Many of these applications are possible with the most widely available PET tracer, 2-deoxy-2-[18F]fluoro-D-glucose (FDG). Additional tracers are used clinically to detect the disturbance of specific neurotransmitter and receptor systems, blood flow, oxygen metabolism, and amino acid uptake. Main diagnostic issues addressed in this review are early diagnosis of Alzheimer's disease and other dementias, differential diagnosis of movement disorders, diagnosis of recurrent brain tumors, identification of viable tissue in ischemic stroke, and localization of epileptogenic foci. Techniques for presurgical localization of eloquent cortex and monitoring of therapy are presented.

Entities:  

Mesh:

Year:  2004        PMID: 15262239     DOI: 10.1016/j.mibio.2004.05.002

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  13 in total

Review 1.  Molecular imaging of brain tumors: a bridge between clinical and molecular medicine?

Authors:  B J Schaller; M Modo; M Buchfelder
Journal:  Mol Imaging Biol       Date:  2007 Mar-Apr       Impact factor: 3.488

2.  Activity-based costing evaluation of [18F]-fludeoxyglucose production.

Authors:  Bruno Krug; Annie Van Zanten; Anne-Sophie Pirson; Ralph Crott; Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-21       Impact factor: 9.236

3.  Fast and repetitive in-capillary production of [18F]FDG.

Authors:  Hans-Jürgen Wester; Bent Wilhelm Schoultz; Christina Hultsch; Gjermund Henriksen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-27       Impact factor: 9.236

4.  Molecular medicine successes in neuroscience.

Authors:  Bernhard Schaller; Jan F Cornelius; Nora Sandu
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

5.  Small-animal PET demonstrates brain metabolic change after using bevacizumab in a rat model of cerebral ischemic injury.

Authors:  Ying Dong; Fahuan Song; Jianjuan Ma; Xuexin He; Said Amer; Weizhong Gu; Mei Tian
Journal:  Neurosci Bull       Date:  2014-09-28       Impact factor: 5.203

6.  The Clinical Value of PET with Amino Acid Tracers for Gliomas WHO Grade II.

Authors:  Anja Smits; Brigitta G Baumert
Journal:  Int J Mol Imaging       Date:  2011-04-28

7.  Cerebral Microdialysis-Based Interventions Targeting Delayed Cerebral Ischemia Following Aneurysmal Subarachnoid Hemorrhage.

Authors:  Jakob Winberg; Isabella Holm; David Cederberg; Malin Rundgren; Erik Kronvall; Niklas Marklund
Journal:  Neurocrit Care       Date:  2022-04-29       Impact factor: 3.532

8.  Gamma knife treatment for refractory epilepsy in seizure focus localized by positron emission tomography/CT.

Authors:  Xia Bai; Xuemei Wang; Hongwei Wang; Shigang Zhao; Xiaodong Han; Linjun Hao; Xiangcheng Wang
Journal:  Neural Regen Res       Date:  2012-12-25       Impact factor: 5.135

Review 9.  Biomarker selection and imaging design in cancer: A link with biochemical pathways for imminent engineering.

Authors:  Joham Surfraz Ali; Noor Ul Ain; Sania Naz; Muhammad Zia
Journal:  Heliyon       Date:  2020-02-03

Review 10.  (13)C NMR spectroscopy applications to brain energy metabolism.

Authors:  Tiago B Rodrigues; Julien Valette; Anne-Karine Bouzier-Sore
Journal:  Front Neuroenergetics       Date:  2013-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.